<DOC>
	<DOCNO>NCT01086722</DOCNO>
	<brief_summary>Morbid obesity ( MO ) associate several disorder hypertension , type 2 diabetes , dyslipemia degenerative arthropathy require pharmacological treatment . Drug bioavailability metabolism patient MO alter compare population control . Bariatric surgery gold standard treatment MO conventional therapy fails . Bariatric surgery technique modify drug absorption MO patient . These modification depend drug absorption characteristic bariatric surgery technique use . The change weight body composition cause BS middle term alter drug bioavailability metabolism . The kinetics `` normalization '' process patient MO bariatric surgery unknown Objectives . To analyze change drug metabolism pharmacokinetics . To establish drug dose criterion post-intervention period patient MO bariatric surgery . To determine relationship change drug bioavailability metabolism MO bariatric surgery ( longitudinal gastrectomy Y-roux gastric by-pass ) .</brief_summary>
	<brief_title>Pharmacokinetics Morbid Obesity After Bariatric Surgery</brief_title>
	<detailed_description>Patients method . A prospective study two cohort patient program bariatric surgery ( gastric by-pass sleeve gastrectomy ) . Study `` '' . Evaluations . Study drug metabolism pharmacokinetics use modify `` karolinska cocktail '' ( dextromethorphan , caffeine , losartan , omeprazole paracetamol ) bariatric surgery 4 week 6 month post-intervention .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<criteria>Adults ( 18 55 year ) Morbid Obesity BMI &gt; 40 BMI &gt; 35 plus comorbidity Healthy control ( nonoverweight overweight group ) Allergy study drug Liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>